AD\u00dc Teknokent\u2019te \u00e7al\u0131\u015fmalar\u0131n\u0131 s\u00fcrd\u00fcren Karya Farma HBX Ar-Ge ekibi, yeni nesil ak\u0131ll\u0131 antibiyotik \u00fczerinde \u00e7al\u0131\u015fma yapt\u0131\u011f\u0131n\u0131 duyurdu. HBX-2371 metodolojisi ad\u0131yla tan\u0131mlanan bu yakla\u015f\u0131m\u0131n, klasik antibiyotiklerden farkl\u0131 olarak tek y\u00f6nl\u00fc bir etki yerine \u00e7oklu biyolojik etki a\u011flar\u0131 \u00fczerinden \u00e7al\u0131\u015ft\u0131\u011f\u0131 belirtildi.
\n
T\u00fcrkiye\u2019de geli\u015ftirilen ve T\u00fcrk Patent ve Marka Kurumu taraf\u0131ndan tescillenen \u00e7ok say\u0131da HBX patentinin ortak etki mekanizmalar\u0131n\u0131n bir araya getirilmesiyle olu\u015fturulan \u00e7al\u0131\u015fmaya ili\u015fkin bilgi veren Karya Farma HBX Ar-Ge Kurucusu Hakan Ba\u015fl\u0131k, “HBX-2371 metodolojisi ad\u0131yla tan\u0131mlanan bu yakla\u015f\u0131m, klasik antibiyotiklerden farkl\u0131 olarak tek y\u00f6nl\u00fc bir etki yerine \u00e7oklu biyolojik etki a\u011flar\u0131 \u00fczerinden \u00e7al\u0131\u015f\u0131yor. Tek bir hedef de\u011fil, ak\u0131ll\u0131 bir etki a\u011f\u0131na sahip. HBX patentleri incelendi\u011finde; antibakteriyel, antiviral, antifungal, antiparazitik, antikanser, antit\u00fcm\u00f6r, yara iyile\u015ftirici, rejeneratif ve ba\u011f\u0131\u015f\u0131kl\u0131k g\u00fc\u00e7lendirici \u00f6zelliklerin tek tek de\u011fil, birbirini tamamlayan sistemler halinde tasarland\u0131\u011f\u0131 g\u00f6r\u00fcl\u00fcyor. Bu nedenle elde edilen \u00fcr\u00fcn\u00fc \u2018ak\u0131ll\u0131 antibiyotik\u2019 olarak adland\u0131rd\u0131k” dedi.
\n
HBX-2371 metodolojisinin dikkat \u00e7eken y\u00f6nlerinden birinin de etki mekanizmas\u0131n\u0131 yaln\u0131zca mikrobiyal bask\u0131lama ile s\u0131n\u0131rlamamas\u0131 oldu\u011funu kaydeden Ba\u015fl\u0131k, “A\u011f\u0131z yoluyla al\u0131nan bile\u015fenler beyin-ba\u011f\u0131rsak ekseni \u00fczerinden mide ve sindirim sistemi arac\u0131l\u0131\u011f\u0131yla biyo yararlan\u0131m\u0131 art\u0131r\u0131yor. Kalp ve dola\u015f\u0131m sistemiyle h\u00fccresel seviyeye ula\u015ft\u0131r\u0131lan \u00e7ok katmanl\u0131 bir biyolojik ba\u011flant\u0131 modeli \u00f6ne \u00e7\u0131k\u0131yor. Bu yakla\u015f\u0131m, ba\u011f\u0131\u015f\u0131kl\u0131k sistemini bask\u0131lanan bir savunma hatt\u0131 olarak de\u011fil, yeniden d\u00fczenlenen ve y\u00f6nlendirilen bir sistem olarak ele al\u0131yor. \u00dcr\u00fcn tek bir bakteri ya da vir\u00fcse odaklanmaz, diren\u00e7 geli\u015fimini tetikleyen agresif kimyasal bask\u0131 yerine dengeleyici etki olu\u015fturur, yaln\u0131zca patojeni de\u011fil hasarl\u0131 dokuyu ve ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131n\u0131 da hedef al\u0131r” ifadelerini kulland\u0131.
\n
\u00c7al\u0131\u015fmaya akademik destek sa\u011flayan Prof. Dr. Sami Do\u011fanlar ise bitki tabanl\u0131 ila\u00e7 geli\u015ftirme projeleri kapsam\u0131nda Karya Farma HBX Ar-Ge ile y\u00fcr\u00fct\u00fclen i\u015f birli\u011fini son derece de\u011ferli bulduklar\u0131n\u0131 kaydederek “Yedi spesifik patente dayanan HBX-2371 metodolojisi, klasik antibiyotik yakla\u015f\u0131mlar\u0131n\u0131n \u00f6tesinde, \u00e7ok katmanl\u0131 ve yenilik\u00e7i bir biyoteknolojik perspektif sunmaktad\u0131r” dedi.
<\/p>\n","protected":false},"excerpt":{"rendered":"
AD\u00dc Teknokent\u2019te \u00e7al\u0131\u015fmalar\u0131n\u0131 s\u00fcrd\u00fcren Karya Farma HBX Ar-Ge ekibi, yeni nesil ak\u0131ll\u0131 antibiyotik \u00fczerinde \u00e7al\u0131\u015fma yapt\u0131\u011f\u0131n\u0131 duyurdu. HBX-2371 metodolojisi ad\u0131yla tan\u0131mlanan bu yakla\u015f\u0131m\u0131n, klasik antibiyotiklerden farkl\u0131 olarak tek y\u00f6nl\u00fc bir etki yerine \u00e7oklu biyolojik etki a\u011flar\u0131 \u00fczerinden \u00e7al\u0131\u015ft\u0131\u011f\u0131 belirtildi. T\u00fcrkiye\u2019de geli\u015ftirilen ve T\u00fcrk Patent ve Marka Kurumu taraf\u0131ndan tescillenen \u00e7ok say\u0131da HBX patentinin ortak etki…<\/p>\n","protected":false},"author":1,"featured_media":77876,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_crdt_document":"","footnotes":""},"categories":[124],"tags":[],"class_list":["post-77875","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bilim"],"_links":{"self":[{"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/posts\/77875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77875"}],"version-history":[{"count":1,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/posts\/77875\/revisions"}],"predecessor-version":[{"id":77877,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/posts\/77875\/revisions\/77877"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/media\/77876"}],"wp:attachment":[{"href":"https:\/\/www.egemtv.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}